YUPELRI
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.8M | 28,684 | 12,001 |
| 2023 | $4.2M | 26,696 | 10,617 |
| 2022 | $4,281 | 3 | 2 |
| 2021 | $616,723 | 2,382 | 1,551 |
| 2020 | $126.68 | 8 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.3M | 535 | 70.0% |
| Food and Beverage | $1.2M | 56,082 | 15.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $605,827 | 463 | 8.0% |
| Consulting Fee | $416,888 | 455 | 5.5% |
| Travel and Lodging | $62,363 | 229 | 0.8% |
| Space rental or facility fees (teaching hospital only) | $6,250 | 4 | 0.1% |
| Education | $284.98 | 5 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | Mylan Specialty L.P. | $3.3M | 0 |
| A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | Mylan Specialty L.P. | $938,268 | 0 |
| Prevalence of Impairments in Cognitive Function and Manual Dexterity in Out-patients with COPD and Associations with Correct Inhaler Techniques | Mylan Specialty L.P. | $335,900 | 0 |
| DOM-19001 | Mylan Specialty L.P. | $285,000 | 1 |
| Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO) | Mylan Specialty L.P. | $226,091 | 0 |
| Differentiating the Effects of Long-acting Bronchodilators Administered by Nebulizer versus Dry Powder Inhaler in Symptomatic Patients with Chronic Obstructive Pulmonary Disease | Mylan Specialty L.P. | $109,886 | 0 |
| A qualitative study to understand patient & social factors related to nebulizer use at the transition of care in COPD | Mylan Specialty L.P. | $51,576 | 0 |
| Long-acting Bronchodilators Administered by Nebulizer vs Dry Powder Inhaler in Symptomatic Patients with Chronic Obstructive Pulmonary Disease | Mylan Specialty L.P. | $41,572 | 0 |
| Identifying Clinically Relevant PIF Cutoffs | Mylan Specialty L.P. | $28,800 | 0 |
Top Doctors Receiving Payments for YUPELRI — Page 726
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Charlotte, NC | $11.68 | 1 |
| , MD | Pulmonary Disease | Charlotte, NC | $11.68 | 1 |
| , MD | Internal Medicine | Charlotte, NC | $11.68 | 1 |
| , M.D | Allergy & Immunology | Beaumont, TX | $11.62 | 1 |
| , NP | Family | Lumberton, TX | $11.62 | 1 |
| , PA-C | Medical | Charlotte, NC | $11.61 | 1 |
| Jason Perlman | Family Medicine | Charlotte, NC | $11.61 | 1 |
| , M.D | Family Medicine | Wichita, KS | $11.60 | 1 |
| , PA | Medical | Wichita, KS | $11.60 | 1 |
| , DO | Adolescent Medicine | Brooklyn, IA | $11.50 | 1 |
| , APN | Acute Care | Denver, CO | $11.41 | 1 |
| , M.D | Pulmonary Disease | Greenwood Village, CO | $11.40 | 1 |
| , MSN, ACNP-BC | Acute Care | Beaumont, TX | $11.37 | 1 |
| , M.D | Family Medicine | Beaumont, TX | $11.37 | 1 |
| , D.O | Internal Medicine | Hazard, KY | $11.30 | 1 |
| , APRN | Family | Hazard, KY | $11.30 | 1 |
Manufacturing Companies
- Mylan Specialty L.P. $7.6M
- Mylan Inc. $32,734
- Mylan Pharmaceuticals Inc. $94.30
Product Information
- Type Drug
- Total Payments $7.6M
- Total Doctors 18,140
- Transactions 57,773
About YUPELRI
YUPELRI is a drug associated with $7.6M in payments to 18,140 healthcare providers, recorded across 57,773 transactions in the CMS Open Payments database. The primary manufacturer is Mylan Specialty L.P..
Payment data is available from 2020 to 2024. In 2024, $2.8M was paid across 28,684 transactions to 12,001 doctors.
The most common payment nature for YUPELRI is "Unspecified" ($5.3M, 70.0% of total).
YUPELRI is associated with 9 research studies, including "A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler)" ($3.3M).